The ISO 11137 series (Parts 1, 2, 3) specifies requirements and guidance for development, validation, and routine control of gamma, X-ray, and electron beam sterilization processes. Part 1 covers process development, validation and routine control, Part 2 covers setting the sterilization dose (such as VDmax and Method 1), and Part 3 covers dosimetry. Validation must also show that the maximum acceptable dose does not degrade materials or performance. Once validated, radiation sterilization allows dosimetric release without biological indicators.

Why it matters

Demand for non-EO sterilization is growing; many manufacturers now maintain dual capability and qualify both routes.

Common pitfalls

•Misinterpreting the dose necessary for different product types or bioburden levels can lead to ineffective sterilization or material degradation.
•Failing to re-validate sterilization processes after significant changes to the product, packaging, or manufacturing site can compromise sterility assurance.
•Inadequate documentation of the validation studies and routine monitoring procedures can result in regulatory non-compliance.
•Assuming a universal sterilization dose for all devices without conducting product-specific validation studies is a common error.
•Neglecting to consider the potential impact of radiation on material properties and device functionality can lead to product failures.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.